Prostacyclin

From WikiMD.org
Jump to navigation Jump to search

Prostacyclin (pronounced pro-sta-cy-clin), also known as PGI2, is a prostaglandin member of the eicosanoid family of lipid molecules. It was discovered in 1976 by John Vane and his team.

Etymology

The term "Prostacyclin" is derived from the terms "prostaglandin" and "cyclin". The "prosta" part of the name comes from the prostate gland, where prostaglandins were first isolated. The "cyclin" part of the name refers to the cyclic nature of the molecule's structure.

Function

Prostacyclin is produced in the walls of blood vessels and serves as a potent vasodilator and inhibitor of platelet aggregation. It is synthesized from arachidonic acid by the action of the enzyme cyclooxygenase and prostacyclin synthase. It works by binding to the prostacyclin receptor on the surface of cells, leading to an increase in the intracellular concentration of cyclic AMP.

Clinical significance

Prostacyclin and its analogues are used in the treatment of pulmonary arterial hypertension. They work by dilating the blood vessels in the lungs, reducing the workload on the heart. Prostacyclin is also being investigated for its potential anti-cancer properties.

Related terms

See also

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski